On the one hand, blocking TIM-3 exacerbates disease outcome in various preclinical disease models of multiple sclerosis, inflammatory bowel disease, or diabetes, among others by hyperactivating Th1 cell immune function.36 Here, HAVCR2 is linked to inflammatory bowel disease.